| 產(chǎn)品名稱(chēng) |
Human herpesvirus 3 |
| 商品貨號(hào) |
B162902 |
| Classification |
Herpesviridae, Varicellovirus |
| Deposited As |
Varicella-Zoster |
| Agent |
Human herpesvirus 3 |
| Strain |
AV92-3:L (low passage) |
| Common Name |
Varicella zoster virus |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen |
| Storage Conditions |
Vapor phase of liquid nitrogen |
| Comments |
Frozen infected cells and supernate |
| Effect on Host |
CPE (slowly developing focal rounding and sloughing) |
| Recommended Host |
BS-C-1 cells (ATCC® CCL-26™) |
| Growth Conditions |
Incubation: 5-7 days at 37°C |
| Name of Depositor |
A Vafai |
| Special Collection |
NCRR Contract |
| Source |
Patient with zoster |
| References |
Vafai A. Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein. Vaccine 12: 1265-1269, 1994. PubMed: 7531921
|
